Skip Navigation

Adalvo Restarts Regulatory Procedures for Ethinylestradiol + Drospirenone DCP

20 March 2024

Adalvo is pleased to announce the restart of the DCP procedure for Ethinylestradiol + Drospirenone 0.03 mg/3 mg, with an anticipated approval date in July 2024.

Based on the reference brand Yasmin, Ethinylestradiol + Drospirenone has been developed in collaboration with one of our strategic partners. The INN is a low-dose oral contraceptive that generated approximately $826mio in global sales in 2023, according to IQVIA.

The development of Ethinylestradiol + Drospirenone showcases Adalvo's capability to host a diverse and comprehensive women's health portfolio.

At Adalvo, there are no half-measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.

Click Here To Get In Touch!